[Form 4] Zomedica Corp. Insider Trading Activity

Rhea-AI Filing Summary

Zomedica Corp. reporting person Kevin Klass, Sr. Vice President of Sales, reported purchases on 08/11/2025 totaling 500,000 common shares in two transactions: 250,000 shares at $0.038 and 250,000 shares at $0.04. The filings show direct beneficial ownership rising to 4,200,030 shares. The Form 4 is signed on 08/12/2025. No derivative transactions are reported.

Positive

• Insider acquisitions: Reporting person purchased a total of 500,000 common shares on 08/11/2025.
• Increased direct ownership: Direct beneficial ownership is reported at 4,200,030 shares following the transactions.

Negative

• None.

Insights

Securities Analyst

TL;DR Insider Kevin Klass reported purchases of 500,000 Zomedica common shares, increasing direct holdings to 4.2M shares.

The Form 4 discloses two purchase transactions on 08/11/2025: 250,000 shares at $0.038 and 250,000 shares at $0.04. The filings list direct ownership and show no derivative activity. This is a standard Section 16 disclosure documenting insider acquisitions and the signature confirms filing on 08/12/2025.

Corporate Governance Expert

TL;DR Officer and reporting person Kevin Klass acquired 500,000 Zomedica shares directly; the Form 4 reflects routine insider reporting.

The document identifies Klass as Sr. Vice President of Sales and reports two non-derivative purchases executed 08/11/2025. Beneficial ownership is reported on a direct basis, culminating at 4,200,030 shares. The form is a standard disclosure with no amendments or derivative entries.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klass Russell Kevin

(Last) (First) (Middle)

1101 TECHNOLOGY DRIVE.

STE 100 ANN ARBOR, MI 48108

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr Vice President of Sales

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, without par value	08/11/2025		P		250,000	A	$0.038	3,950,030	D
Common Stock, without par value	08/11/2025		P		250,000	A	$0.04	4,200,030	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kevin Klass	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions were reported for Zomedica (ZOMDF)?

The Form 4 reports two purchases on 08/11/2025: 250,000 shares at $0.038 and 250,000 shares at $0.04.

Who filed the Form 4 for Zomedica?

The filing was made by Kevin Klass, identified as Sr. Vice President of Sales and an officer of the issuer.

How many Zomedica shares does the reporting person own after the transactions?

The Form 4 shows direct beneficial ownership of 4,200,030 shares following the reported transactions.

Were any derivative securities reported in this Form 4 for Zomedica?

No. The filing contains no entries in Table II; only non-derivative common stock purchases are reported.

When was the Form 4 signed?

The Form 4 bears the signature of the reporting person and is dated 08/12/2025.